| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Finasteride | FAERS: 15 | US FAERS | |
| 2 | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide | FAERS: 6 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 3 | rofecoxib | FAERS: 5 | OFFSIDES US FAERS | |
| 4 | Lenalidomide | FAERS: 2 | US FAERS | |
| 5 | NuvaRing | FAERS: 2 | US FAERS | |
| 6 | Capecitabine | FAERS: 1 | US FAERS | |
| 7 | Clozapine | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 8 | Imatinib Mesylate | FAERS: 1 | US FAERS | |
| 9 | LCZ 696 | FAERS: 1 | US FAERS | |
| 10 | MDV 3100 | FAERS: 1 | US FAERS | |
| 11 | Midodrine | FAERS: 1 | US FAERS | |
| 12 | Oxcarbazepine | FAERS: 1 | US FAERS | |
| 13 | Sertraline | FAERS: 1 | US FAERS | |
| 14 | Valsartan | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 15 | pazopanib | FAERS: 1 | US FAERS | |
| 16 | Bleomycin | OFFSIDES | ||
| 17 | Bupropion | OFFSIDES | ||
| 18 | Calcitriol | OFFSIDES | ||
| 19 | Carbamazepine | SIDER | ||
| 20 | Carvedilol | OFFSIDES | ||
| 21 | Cisapride | OFFSIDES | ||
| 22 | Clopidogrel | OFFSIDES | ||
| 23 | Dacarbazine | OFFSIDES | ||
| 24 | Flurazepam | OFFSIDES | ||
| 25 | Hydromorphone | OFFSIDES | ||
| 26 | Lactulose | OFFSIDES | ||
| 27 | Metoprolol | SIDER | ||
| 28 | Midodrine | OFFSIDES | ||
| 29 | Mupirocin | OFFSIDES | ||
| 30 | Nitroglycerin | OFFSIDES | ||
| 31 | Pentoxifylline | OFFSIDES | ||
| 32 | Potassium | OFFSIDES | ||
| 33 | Propranolol | SIDER | ||
| 34 | Timolol | SIDER | ||
| 35 | Vinblastine | OFFSIDES | ||
| 36 | Zoledronic Acid | OFFSIDES | ||
| 37 | ambrisentan | OFFSIDES | ||
| 38 | dorzolamide | SIDER | ||
| 39 | prednisolone acetate | OFFSIDES |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120241
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.